The Outcome of COVID-19 in Pediatric-Onset Multiple Sclerosis Patients.
COVID-19
Disease-modifying therapy
Pediatric-onset multiple sclerosis
Severity
Journal
Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
07
12
2021
revised:
18
05
2022
accepted:
04
06
2022
pubmed:
1
7
2022
medline:
17
8
2022
entrez:
30
6
2022
Statut:
ppublish
Résumé
The pathogenesis of multiple sclerosis (MS) involves immune-mediated mechanisms, and disease-modifying therapies (DMTs) administered in MS have immunomodulatory effects. The concern about MS patients' susceptibility to coronavirus disease 2019 (COVID-19) has prompted several studies based on clinical observations and questionnaires. Information about COVID-19 in pediatric-onset multiple sclerosis (POMS) is scarce. The objective of this study was to collect information on the experience of POMS patients with COVID-19 during the pandemic. This cross-sectional study was conducted with POMS patients diagnosed at Hacettepe University Pediatric Neurology Department and under 23 years of age between October 1 and December 31, 2021. Those who experienced COVID-19 or had a history of contact and were found seropositive for COVID-19 were evaluated for the severity of COVID-19, disability, treatment status, and comorbidities. Among the 101 POMS patients, 13 reported having had COVID-19 and five were exposed and seropositive but clinically asymptomatic. Of these 18 patients, 14 were ≤18 years of age at the time of the study. All 13 patients (72%) reported mild symptoms without hospitalization or respiratory support. Four of 18 had a neurological disability (Expanded Disability Status Scale [EDSS] scores ranging between 1 and 7.5), while the remaining had a score of 0. The outcome of COVID-19 was not affected by DMTs, neurological disabilities, and comorbidities. In this single-center POMS series, the small subgroup of patients who had contacted the SARS-CoV-2 virus or developed COVID-19 had reported no or mild symptoms. This may be partly related to the infrequent use of rituximab in this group. Our results corroborate those in adult-onset MS where no increased risk is reported for patients whose EDSS scores are <6 and who are not on B cell-depleting DMTs. Although less frequently than in adult MS, immunosuppressive DMTs may be needed in POMS; therefore, the importance of appropriate vaccination is to be underlined.
Sections du résumé
BACKGROUND
The pathogenesis of multiple sclerosis (MS) involves immune-mediated mechanisms, and disease-modifying therapies (DMTs) administered in MS have immunomodulatory effects. The concern about MS patients' susceptibility to coronavirus disease 2019 (COVID-19) has prompted several studies based on clinical observations and questionnaires. Information about COVID-19 in pediatric-onset multiple sclerosis (POMS) is scarce. The objective of this study was to collect information on the experience of POMS patients with COVID-19 during the pandemic.
METHODS
This cross-sectional study was conducted with POMS patients diagnosed at Hacettepe University Pediatric Neurology Department and under 23 years of age between October 1 and December 31, 2021. Those who experienced COVID-19 or had a history of contact and were found seropositive for COVID-19 were evaluated for the severity of COVID-19, disability, treatment status, and comorbidities.
RESULTS
Among the 101 POMS patients, 13 reported having had COVID-19 and five were exposed and seropositive but clinically asymptomatic. Of these 18 patients, 14 were ≤18 years of age at the time of the study. All 13 patients (72%) reported mild symptoms without hospitalization or respiratory support. Four of 18 had a neurological disability (Expanded Disability Status Scale [EDSS] scores ranging between 1 and 7.5), while the remaining had a score of 0. The outcome of COVID-19 was not affected by DMTs, neurological disabilities, and comorbidities.
CONCLUSIONS
In this single-center POMS series, the small subgroup of patients who had contacted the SARS-CoV-2 virus or developed COVID-19 had reported no or mild symptoms. This may be partly related to the infrequent use of rituximab in this group. Our results corroborate those in adult-onset MS where no increased risk is reported for patients whose EDSS scores are <6 and who are not on B cell-depleting DMTs. Although less frequently than in adult MS, immunosuppressive DMTs may be needed in POMS; therefore, the importance of appropriate vaccination is to be underlined.
Identifiants
pubmed: 35772229
pii: S0887-8994(22)00107-2
doi: 10.1016/j.pediatrneurol.2022.06.004
pmc: PMC9186527
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-10Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Neurol Neuroimmunol Neuroinflamm. 2021 May 20;8(4):
pubmed: 34016734
Neurology. 2019 Jun 11;92(24):e2764-e2773
pubmed: 31092624
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Mult Scler J Exp Transl Clin. 2020 Oct 12;6(4):2055217320966346
pubmed: 33110621
Front Immunol. 2020 Dec 17;11:587078
pubmed: 33391262
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Mult Scler Relat Disord. 2021 Jun;51:102915
pubmed: 33799284
MMWR Morb Mortal Wkly Rep. 2021 Jun 11;70(23):851-857
pubmed: 34111061
JAMA Neurol. 2021 Jun 1;78(6):699-708
pubmed: 33739362
Neurol Neuroimmunol Neuroinflamm. 2020 Jul 9;7(5):
pubmed: 32646885